A PHASE 3 TRIAL OF SJP-002C
Latest Information Update: 25 Jun 2024
At a glance
- Drugs SJP-002C (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 25 Jun 2024 New trial record
- 24 Jun 2024 According to a Sen Jam Pharmaceutical media release, with the anticipation of positive results, company plans to seek FDA approval to commence Phase 3 clinical trials.